Docetaxel-Loaded pluronic P123 polymeric micelles: In vitro and in vivo evaluation

International Journal of Molecular Sciences

Volumn 12, Issue 3, 2011, Pages 1684-1696

  Liu, Zhihong ^a   Liu, Donghua ^a   Wang, Lili ^a   Zhang, Juan ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anticancer efficacy; Cytotoxicity; Docetaxel; Micelles; Pluronic P123

Indexed keywords

DOCETAXEL; POLOXAMER; ANTINEOPLASTIC AGENT; DRUG CARRIER; MICELLE; PLURONIC BLOCK COPOLYMER P123; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ENCAPSULATION; CELL SIZE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG MECHANISM; DRUG RELEASE; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MICELLE; MICELLIZATION; MOUSE; NONHUMAN; PARTICLE SIZE; SOLID TUMOR; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ALLOTRANSPLANTATION; ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; HEPG2 CELL LINE; MELANOMA, EXPERIMENTAL; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HEP G2 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICELLES; POLOXALENE; TAXOIDS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79953319256     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12031684     Document Type: Article

References (49)

1. ®). Cancer Treat. Rev. 1993, 19, 351-386.
2. Cortes, J.E.; Pazdur, R. Docetaxel. J. Clin. Oncol. 1995, 13, 2643-2655.
3. Chevallier, B.; Fumoleau, P.; Kerbrat, P.; Dieras, V.; Roche, H.; Krakowski, I.; Azli, N.; Bayssas, M.; Lentz, M.A.; Van Glabbeke, M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 1995, 13, 314-322.
4. Ravdin, P.M.; Burris, H.A.; Cook, G.; Eisenberg, P.; Kane, M.; Bierman, W.A.; Mortimer, J.; Genevois, E.; Bellet, R.E. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin. Oncol. 1995, 13, 2879-2885.
5. Valero, V.; Holmes, F.A.; Walters, R.S.; Theriault, R.L.; Esparza, L.; Fraschini, G.; Fonseca, G.A.; Bellet, R.E.; Buzdar, A.U.; Hortobagyi, G.N. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J. Clin. Oncol. 1995, 13, 2886-2894.
6. Fossella, F.V.; Lee, J.S.; Shin, D.M.; Calayag, M.; Huber, M.; Perez-Soler, R.; Murphy, W.K.; Lippman, S.; Benner, S.; Glisson, B. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J. Clin. Oncol. 1995, 13, 645-651.
7. ®) in advanced ovarian cancer-an updated overview. Eur. J. Cancer 1997, 33, 2167-2170.
8. Androulakis, N.; Kourousis, C.; Kakolyris, S.; Sarra, E.; Kalbakis, K.; Kalikaki, T.; Kois, S.; Vardakis, N.; Samonis, G.; Georgoulias, V. Monotherapy with docetaxel and granulocyte colony-stimulating factor in advanced gastric cancer. Ann. Oncol. 1998, 9, 54.
9. Couteau, C.; Chouaki, N.; Leyvraz, S.; Oulid-Aissa, D.; Lebecq, A.; Domenge, C.; Groult, V.; Bordessoule, S.; Janot, F.; De Forni, M.; Armand, J.P. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 1999, 81, 457-462.
10. Friedland, D.; Cohen, J.; Miller, R.; Voloshin, M.; Gluckman, R.; Lembersky, B.; Zidar, B.; Keating, M.; Reilly, N.; Dimitt, B. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 1999, 26, 19-23.
11. Zhang, W.; Yuan, S.; Chen, Y.Z.; Yu, S.Y.; Hao, J.G.; Luo, J.Q.; Sha, X.Y.; Fang, X.L. Enhanced antitumor efficacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 2010, 75, 341-353.
12. Engels, F.K.; Mathot, R.A.; Verweij, J. Alternative drug formulations of docetaxel: A review. Anticancer Drugs 2007, 18, 95-103.
13. Yanasarn, N.; Sloat, B.R.; Cui, Z. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int. J. Pharm. 2009, 379, 174-180.
14. Baker, J.; Ajani, J.; Scotte, F.; Winther, D.; Martin, M.; Aapro, M.S.; Minckwitz, G.V. Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs. 2009, 13, 49-59.
15. Baker, J.; Ajani, J.; Scotte, F.; Winther, D.; Martin, M.; Aapro, M.S.; Minckwitz, G.V. Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs. 2008, 12, 479-479.
16. Zhai, G.; Wu, J.; Xiang, G.; Mao, W.; Yu, B.; Li, H.; Piao, L.; Lee, L.J.; Lee, R.J. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J. Nanosci. Nanotech. 2009, 9, 2155-2161.
17. Huang, H.B.; Liu, T.; Lin, Z.C.; Zhong, J.T.; Lin, P.L.; Liu, J.Y.; Tan, Y.Y.; Li, S.; Liao, H.; Xu, Y.H. Preparation of docetaxel liposomes and their pharmacokinetics in rabbits. Ai Zheng 2007, 26, 1287-1291.
18. Immordino, M.L.; Brusa, P.; Arpicco, S.; Stella, B.; Dosio, F.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 2003, 91, 417-429.
19. Musumeci, T.; Ventura, C.A.; Giannone, I.; Ruozi, B.; Montenegro, L.; Pignatello, R.; Puglisi, G. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 2006, 325, 172-179.
20. Yin, Y.M.; Cui, F.D.; Mu, C.F.; Choi, M.K.; Kim, J.S.; Chung, S.J.; Shim, C.K.; Kim, D.D. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J. Control. Release 2009, 140, 86-94.
21. Gao, K.; Sun, J.; Liu, K.; Liu, X.; He, Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: Submicron lipid emulsion of docetaxel. Drug Dev. Ind. Pharm. 2008, 34, 1227-1237.
22. Esmaeili, F.; Dinarvand, R.; Ghahremani, M.H.; Amini, M.; Rouhani, H.; Sepehri, N.; Ostad, S.N.; Atyabi, F. Docetaxel-albumin conjugates: Preparation, in vitro evaluation and biodistribution studies. J. Pharm. Sci. 2009, 98, 2718-2730.
23. Liu, J.; Zahedi, P.; Zeng, F.; Allen, C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J. Pharm. Sci. 2008, 97, 3274-3290.
24. Xie, Z.G.; Lu, T.C.; Chen, X.S.; Zheng, Y.H.; Jing, X.B. Synthesis, self-assembly in water, and cytotoxicity of MPEG-block-PLLA/DX conjugates. J. Biomed. Mater. Res. A 2009, 88A, 238-245.
25. Mikhail, A.S.; Allen, C. Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels. J. Control. Release 2009, 138, 214-223.
26. Nishiyama, N.; Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 2006, 112, 630-648.
27. Bae, Y.; Kataoka, K. Intelligent polymeric micelles from functional poly (ethylene glycol)-poly (amino acid) block copolymers. Adv. Drug Deliv. Rev. 2009, 61, 768-784.
28. Gaucher, G.; Dufresne, M.H.; Sant, V.P.; Kang, N.; Maysinger, D.; Leroux, J.C. Block copolymer micelles: Preparation, characterization and application in drug delivery. J. Control. Release 2005, 109, 169-188.
29. Lukyanov, A.N.; Torchilin, V.P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug Deliv. Rev. 2004, 56, 1273-1289.
30. Elsabahy, M.; Perron, M.E.; Bertrand, N.; Yu, G.E.; Leroux, J.C. Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles. Biomacromolecules 2007, 8, 2250-2257.
31. Mikhail, A.S.; Allen, C. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: Synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 2010, 11, 1273-1280.
32. Batrakova, E.V.; Li, S.; Li, Y.L.; Alakhov, V.Y.; Elmquist, W.F.; Kabanov, A.V. Distribution kinetics of a micelle-forming block copolymer Pluronic P85. J. Control. Release 2004, 100, 389-397.
33. Zhang, W.; Hao, J.G.; Yuan, S.; Li, Y.J.; Juan, W.; Sha, X.Y.; Fang, X.L. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: Formulation, optimization and in vitro characterization. Int. J. Pharm. 2009, 376, 176-185.
34. Han, L.M.; Guo, J.; Zhang, L.J.; Wang, Q.S.; Fang, X.L. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with pluronic P123. Acta Pharmacol. Sin. 2006, 27, 747-753.
35. ® block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 2002, 82, 189-212.
36. Foster, B.; Cosgrove, T.; Hammouda, B. Pluronic triblock copolymer systems and their interactions with ibuprofen. Langmuir 2009, 25, 6760-6766.
37. Bae, Y.H.; Yin, H.Q. Stability issues of polymeric micelles. J. Control. Release 2008, 131, 2-4.
38. Mu, L.; Teo, M.M.; Ning, H.Z.; Tan, C.S.; Feng, S.S. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: Application and investigation of TPGS and PEG in spray-dried particulate system. J. Control. Release 2005, 103, 565-575.
39. Dong, P.W.; Wang, X.H.; Gu, Y.C.; Wang, Y.J.; Wang, Y.J.; Gong, C.Y.; Luo, F.; Guo, G.; Zhao, X.; Wei, Y.Q.; Qian, Z.Y. Self-assembled biodegradable micelles based on star-shaped PCL-b-PEG copolymers for chemotherapeutic drug delivery. Colloid. Surface A 2010, 358, 128-134.
40. Danhier, F.; Magotteaux, N.; Ucakar, B.; Lecouturier, N.; Brewster, M.; Preat, V. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for Paclitaxel. Eur. J. Pharm. Biopharm. 2009, 73, 230-238.
41. Jones, M.; Leroux, J. Polymeric micelles-A new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 1999, 48, 101-111.
42. Matsumura, Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 2010, in press.
43. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2010, in press.
44. De Jong, W.H.; Borm, P.J.A. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 2008, 3, 133-149.
45. Chen, W.Q.; Wei, H.; Li, S.L.; Feng, J.; Nie, J.; Zhang, X.Z.; Zhuo, R.X. Fabrication of star-shaped, thermo-sensitive poly(N-isopropylacrylamide)-cholic acid-poly(epsilon-caprolactone) copolymers and their self-assembled micelles as drug carriers. Polymer 2008, 49, 3965-3972.
46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Meth. 1983, 65, 55-63.
47. Danhier, F.; Lecouturier, N.; Vroman, B.; Jerome, C.; Marchand-Brynaert, J.; Feron, O.; Preat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control. Release 2009, 133, 11-17.
48. Zheng, D.H.; Li, X.L.; Xu, H.E.; Lu, X.W.; Hu, Y.; Fan, W.X. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim. Biophys. Sin. 2009, 41, 578-587.
49. Zhao, Z.M.; He, M.; Yin, L.C.; Bao, J.M.; Shi, L.L.; Wang, B.Q.; Tang, C.; Yin, C.H. Biodegradable nanoparticles based on linoleic acid and poly(beta-malic acid) double grafted chitosan derivatives as carriers of anticancer drugs. Biomacromolecules 2009, 10, 565-572.